US20160287594A1 - Compositions Containing Ibrutinib - Google Patents

Compositions Containing Ibrutinib Download PDF

Info

Publication number
US20160287594A1
US20160287594A1 US15/092,195 US201615092195A US2016287594A1 US 20160287594 A1 US20160287594 A1 US 20160287594A1 US 201615092195 A US201615092195 A US 201615092195A US 2016287594 A1 US2016287594 A1 US 2016287594A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
sodium
ibrutinib
magnesium stearate
lauryl sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/092,195
Other languages
English (en)
Inventor
Manish Kumar Gupta
Kaustubh Tambwekar
Binuraj Krishnan Nair
Dilip J. Gole
Maristella Bernini
Sabine Inghelbrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20160287594(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to US15/092,195 priority Critical patent/US20160287594A1/en
Publication of US20160287594A1 publication Critical patent/US20160287594A1/en
Assigned to JANSSEN PHARMACEUTICA NV reassignment JANSSEN PHARMACEUTICA NV ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NAIR, Binuraj Krishnan, BERNINI, Maristella, GOLE, DILIP, GUPTA, MANISH, TAMBWEKAR, Kaustubh, INGHELBRECHT, Sabine
Priority to US15/602,989 priority patent/US20170252344A1/en
Priority to US16/708,929 priority patent/US20200171036A1/en
Priority to US17/706,783 priority patent/US20220211713A1/en
Priority to US18/304,685 priority patent/US20230263804A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A23L1/30—
    • A23L1/304—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Definitions

  • compositions comprising Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.
  • the composition contains about 40 to about 45% by weight of Ibrutinib.
  • compositions comprising (i) about 40 to about 45% by weight of Ibrutinib; (ii) about 44 to about 47% by weight of microcrystalline cellulose; (iii) about 6 to about 8% by weight of croscarmellose sodium; (iv) about 1 to about 5% by weight of sodium lauryl sulfate; and (v) about 0.2 to about 0.3% by weight of magnesium stearate.
  • compositions comprising (i) about 50 mg of Ibrutinib; (ii) about 54 mg of microcrystalline cellulose; (iii) about 8 mg of croscarmellose sodium; (iv) about 5 mg of sodium lauryl sulfate; and (v) about 0.6 mg of magnesium stearate.
  • capsules or sachets comprising at least one of the pharmaceutical compositions described herein.
  • the capsule is a standard or sprinkle.
  • compositions comprising (i) about 70 mg/mL of Ibrutinib; (ii) about 13 mg/mL of a combination of microcrystalline cellulose and carboxymethylcellulose sodium; (iii) about 2.5 mg/mL of hydroxypropylmethylcellulose; (iv) about 1.5 mg/mL of citric acid monohydrate; (v) about 1.4 mg/mL of disodium hydrogen phosphate; (vi) about 1 mg/mL of sucralose; (vii) about 1 mg/mL of sodium methyl parahydroxybenzoate; and (viii) about 0.6 mg/mL of sodium ethyl parahydroxybenzoate.
  • compositions comprising (i) about 40 mg/mL of Ibrutinib; (ii) about 14 mg/mL of a combination of microcrystalline cellulose and carboxymethylcellulose sodium; (iii) about 1 mg/mL of hydroxypropylmethylcellulose; (iv) about 1.5 mg/mL of citric acid monohydrate; (v) about 1.4 mg/mL of disodium hydrogen phosphate; (vi) about 0.5 mg/mL of sucralose; (vii) about 1.4 mg/mL of sodium methyl parahydroxybenzoate; and (viii) about 0.6 mg/mL of sodium ethyl parahydroxybenzoate.
  • methods for treating a B-cell proliferative disorder comprising the steps of administering at least one pharmaceutical composition described herein to a subject in need thereof.
  • the B-cell proliferative disorder is a non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, plasma cell myeloma, or chronic lymphocytic leukemia.
  • methods for treating mantle cell lymphoma in a subject who has already received at least one prior therapy for mantle cell lymphoma comprising administering at least one composition described herein to the subject once per day.
  • FIG. 1 provides a process flow diagram for preparing capsules containing Ibrutinib.
  • gradations used in a series of values may be used to determine the intended range available to the term “about” or “substantially” for each value. Where present, all ranges are inclusive and combinable. That is, references to values stated in ranges include every value within that range.
  • subject refers to an animal being treated for a condition requiring Ibrutinib.
  • the subject is a human.
  • the subject is an adult, including a young adult, mature adult, or elderly adult, or child, including a teenager.
  • the term “purified” as used herein preferably refers to Ibrutinib that contains less than about 1% impurities. In one embodiment, the Ibrutinib contains less than about 0.5% impurities. In another embodiment, the Ibrutinib contains less than about 0.1% impurities. In a further embodiment, the Ibrutinib is about 100% pure.
  • intragranular and extragranular as used herein are known in the art of formulations.
  • An intragranular form of a formulation component is added before granule formation.
  • an extragranular form of a formulation component is added to the granules of the formulation prior to compression. Simply stated, the extragranular portion breaks the composition into granules and the intragranular portion disintegrates the granules to release the Ibrutinib, a salt, prodrug, or metabolite thereof.
  • CCS croscarmellose sodium
  • MCC microcrystalline cellulose
  • SLS sodium lauryl sulfate
  • HPMC hydroxypropylmethylcellulose; hypromellose
  • DSC differential scanning calorimeter
  • BHT butylated hydroxytoluene
  • BHA butylated hydroxyanisole
  • sodium methyl parahydroxybenzoate sodium ethyl
  • CLL chronic lymphocytic leukemia
  • SLL small lymphocytic lymphoma
  • the Ibrutinib form utilized herein may encompass tautomeric forms of Ibrutinib, prodrugs and salts.
  • the Ibrutinib salts may be derived from pharmaceutically or physiologically acceptable acids, bases, alkali metals and alkaline earth metals.
  • Physiologically acceptable acids include those from inorganic and organic acids. Inorganic acids are known in the art and include, without limitation, hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric, and phosphoric acids.
  • Organic acids are also known in the art and include, without limitation, lactic, formic, acetic, fumaric, citric, propionic, oxalic, succinic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, tartaric, malonic, mallic, phenylacetic, mandelic, embonic, methanesulfonic, ethanesulfonic, panthenoic, benzenesulfonic, toluenesulfonic, stearic, sulfanilic, alginic, and galacturonic acids.
  • Inorganic bases include, without limitation, aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc sulfate or phosphates.
  • organic bases are known in the art and include, without limitation, N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, and procaine.
  • Alkali salts and alkaline earth metal salts can include, without limitation, sodium, potassium, calcium and magnesium salts in the form of esters, and carbamates.
  • Prodrugs of Ibrutinib are also contemplated and include, without limitation, esters, carbamates, sulfates, ethers, oximes, carbonates, among others.
  • the prodrug forms which, when administered in such form, convert to the active moiety in vivo. See, Testa, “Prodrugs Revisited: The “Ad Hoc” Approach as a Complement to Ligand Design”, Medicinal Research Reviews, 16(3):233-241, ed., John Wiley & Sons (1996), which is incorporated by reference.
  • a “metabolite” of Ibrutinib may also be utilized as described herein.
  • a metabolite is a compound of Ibrutinib formed when the compound is metabolized as described in “The Pharmacological Basis of Therapeutics,” 9th Edition, McGraw-Hill (1996), which is incorporated by reference.
  • Ibrutinib may be formulated in solid formulations for administration to a subject.
  • the solid formulation is substantially dry, i.e., free from liquid. In one embodiment, the solid formulation is about 90% or greater dry.
  • the composition contains about 40 to about 45% by weight of Ibrutinib, a salt, prodrug, or metabolite thereof. In one embodiment, the composition contains about 41 to about 44% by weight of Ibrutinib, a salt, prodrug, or metabolite thereof. In a further embodiment, the composition contains about 42 to about 43% by weight of Ibrutinib, a salt, prodrug, or metabolite thereof. In another embodiment, the composition contains about 42 or about 43% by weight of Ibrutinib, a salt, prodrug, or metabolite thereof. In yet a further embodiment, the composition contains about 50 to about 140 mg of Ibrutinib, a salt, prodrug, or metabolite thereof. In still another embodiment, the composition contains about 50 mg of Ibrutinib, a salt, prodrug, or metabolite thereof.
  • One or more suspending agent may be included in the liquid composition discussed herein.
  • microcrystalline cellulose is also included in the compositions described herein.
  • the composition contains about 44 to about 47% by weight of microcrystalline cellulose.
  • the composition contains about 45 to about 46% by weight of microcrystalline cellulose.
  • the compositions may also contain croscarmellose sodium.
  • the croscarmellose sodium may be in an intragranular or extragranular form.
  • the composition contains about 6 to about 8% by weight of croscarmellose sodium.
  • the composition contains about 7% by weight of croscarmellose sodium.
  • the composition contains about 3 to about 5% by weight of intragranular croscarmellose sodium.
  • the composition contains about 4% by weight of intragranular croscarmellose sodium.
  • the composition contains about 2 to about 4% by weight of extragranular croscarmellose sodium.
  • the composition contains about 3% by weight of croscarmellose sodium.
  • a pharmaceutical composition in one embodiment, includes an intragranulation containing Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.
  • a pharmaceutical composition in a further embodiment, contains (i) about 40 to about 45% by weight of Ibrutinib; (ii) about 44 to about 47% by weight of microcrystalline cellulose; (iii) about 6 to about 8% by weight of croscarmellose sodium; (iv) about 1 to about 5% by weight of sodium lauryl sulfate; and (v) about 0.2 to about 0.3% by weight of magnesium stearate.
  • a pharmaceutical composition in still another embodiment, contains (i) about 140 mg of Ibrutinib; (ii) about 151 mg of microcrystalline cellulose; (iii) about 23 mg of croscarmellose sodium; (iv) about 14 mg of sodium lauryl sulfate; and (v) about 1.6 mg of magnesium stearate.
  • the solid compositions described herein contain particles of an optimal size to permit dissolution of the composition, e.g., the particles are less than or equal to about 10 ⁇ .
  • the sizes of the particles of the composition may be measured by passing the solid composition through screens of varying sizes. If the particles of the composition are larger than the optimal size and if the same have not yet been encapsulated in a capsule or dissolved in one or more excipient, the same can be subject to further milling and screening steps, among others, to reduce the particle size.
  • Ibrutinib may optionally be micronized under nitrogen and conventional micronizing techniques, for example with a Trost or jet mill, applied to non-micronized Ibrutinib.
  • compositions described herein are not limited to the method by which the Ibrutinib is produced.
  • Ibrutinib may have a median particle size of less than about 10 ⁇ m, less than about 7 ⁇ m, or than about 5 ⁇ m. Specifically, 90% of the particles are less than or equal to about 10 ⁇ m and 50% are less than or equal to about 10 ⁇ m as determined by the Malvern method, which is readily understood by one of skill in the art.
  • a variety of equipment may be utilized to perform the manufacturing processes of preparing the solid compositions and includes bags of small, medium, and large sizes, screens of varying sizes, and blenders.
  • the process may also include mixing, extruding, fusing, compacting and/or milling of the composition, typically using compactors and mills selected by those skilled in the art.
  • the milling step may be performed on particles of varying sizes, i.e., large particles, powders, and fine powders to obtain a more uniform particle size.
  • the milling may include one or more separating, recycling, and screening steps to obtain the desired particle sizes.
  • the compositions may be prepared by dry mixing Ibrutinib, based upon the total weight of the composition, with the other components of the composition.
  • compositions described herein are prepared by wet mixing Ibrutinib, based upon the total weight of the composition, with the other components of the composition. Drying may be performed using drying instruments selected by one of skill in the art. See, e.g., Lachman, “The Theory and Practice of Industrial Pharmacy”, 3 rd ed. (1986), which is incorporated by reference.
  • the solid compositions discussed herein are prepared by (a) blending microcrystalline cellulose, a first portion of sodium lauryl sulfate, and a first portion of croscarmellose sodium; (b) blending the product of step (a) with a first portion of Ibrutinib; (c) blending the product of step (b) with a second portion of Ibrutinib; (d) blending the product of step (c) with a first portion of magnesium stearate; (e) roller compacting the product of step (d); (0 milling the ribbons produced in step (e); (g) blending the granules produced in step (0 with a second portion of sodium lauryl sulfate and croscarmellose sodium; and (h) blending the product of step (g) with a second portion of magnesium stearate.
  • the solid compositions are prepared as described in FIG. 1 .
  • the solid compositions may then be formed into a suitable dosing unit for delivery to a patient as determined by one skilled in the art.
  • Suitable dosing units include oral dosing units.
  • the composition is added to a capsule.
  • the capsule is for pediatric administration.
  • the capsule is for administration by an adult who is incapable of swallowing a solid drug formulation.
  • the capsule is a HPMC (hypromellose) capsule.
  • the capsule is a gelatin capsule.
  • the capsule is a hard gelatin capsule.
  • the capsule is a standard or sprinkle capsule.
  • the capsule is a Swedish orange capsule.
  • the capsule is a size 0 capsule.
  • the sprinkle capsule may be opened and the contents added to a substance such as a food or drink which may be ingested by the subject.
  • the food may be a semi-solid or a solid, including soft food.
  • the capsules containing Ibrutinib are film-coated.
  • suitable film-coatings are known to those of skill in the art.
  • the film-coating may be a polymer such as HPMC, ethyl cellulose, polyvinyl alcohol, or combinations thereof.
  • the solid compositions may also be added to a sachet.
  • sachet refers to a bag or case which is capable of holding a composition described herein.
  • the size of the sachet depends on the amount of the composition to be added. In one embodiment, the sachet is a single dose sachet. In another embodiment, the sachet contains a bulk amount of the compositions described herein. In the latter case, the patient, physician, or caretaker measures the appropriate dosage of the compositions for administration.
  • the sachet is a paper/aluminum/polyethylene laminate or polyester/aluminum/polyethylene laminate, both of which may optionally be located with a barrier coating such as ethylenevinyl acetate, polyvinyl acetate, polysiloxane, or melamine, among others.
  • the sachet may be opened and the contents added to a substance such as a food or drink which may be ingested by the subject.
  • the drink may include, without limitation, water, milk, or other common beverages.
  • the liquid formulation of solid composition may be administered to a subject via a feeding tube.
  • the feeding tube may be temporarily or permanently affixed to a patient using skill in the art.
  • the patient may be conscious, semi-conscious, or asleep, depending on the need as determined by the attending physician.
  • Several types of feeding tubes are known in the art and may be selected by the attending physician.
  • Ibrutinib may be also formulated in liquid formulations for administration to a subject.
  • Liquids include, without limitation, suspensions, syrups, and elixirs. These dosing units are readily prepared using the methods described herein and those known to those of skill in the art. When formulated as suspension, particle settling may occur, thereby requiring resuspending particles in the suspension using skill in the art.
  • liquid compositions described herein contain Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.
  • the liquid composition contains about 30 to about 80 mg/mL of Ibrutinib, a salt, prodrug, or metabolite thereof. In some embodiments, the composition contains about 30 to about 50 mg/mL of Ibrutinib, a salt, prodrug, or metabolite thereof. In further embodiments, the composition contains about 40 mg/mL of Ibrutinib, a salt, prodrug, or metabolite thereof. In other embodiments, the composition contains about 60 to about 80 mg/mL to about 70 mg/mL of Ibrutinib, a salt, prodrug, or metabolite thereof. In yet further embodiments, the composition contains about 70 mg/mL of Ibrutinib, a salt, prodrug, or metabolite thereof.
  • the buffering agent is citric acid monohydrate or disodium hydrogen phosphate.
  • the composition contains about 2.5 to about 3.5 mg/mL of a buffering agent. In some embodiments, the composition contains about 1 to about 1.5 mg/mL of a first buffering agent. In other embodiments, the composition contains about 0.5 to about 0.7 mg/mL of the buffering agent. In a further embodiment, the composition contains about 1.5 mg/mL of a first buffering agent and about 1.5 mg/mL of a second buffering agent. In other embodiments, the composition contains about 1.6 mg/mL of a first buffering agent and about 1.4 mg/mL of a second buffering agent. In yet another embodiment, the composition contains about 1.5 mg/mL or 1.6 mg/mL of citric acid monohydrate. In still a further embodiment, the composition contains about 1.4 mg/mL of disodium hydrogen phosphate.
  • Sweeteners may also be included in the compositions, solid or liquid, described herein.
  • the sweeter is sucralose.
  • the composition contains about 0.1 to about 1.5 mg/mL of the sweetener.
  • the composition contains 0.5 to about 1.5 mg/mL of the sweetener.
  • the composition contains about 1 mg/mL of the sweetener.
  • the composition contains about 0.5 mg/mL of the sweetener.
  • the composition contains about 1.0 to about 1.8 mg/mL of a first preservative. In still a further embodiment, the composition contains about 1.25 to about 1.5 mg/mL of a second preservative. In another embodiment, the composition contains about 1.1 mg/mL of a first preservative and about 0.6 mg/mL of a second preservative. In other embodiments, the composition contains about 1.4 mg/mL of a first preservative and about 0.7 mg/mL of a second preservative. In yet a further embodiment, the composition contains about 1 mg/mL of sodium methyl parahydroxybenzoate. In still another embodiment, the composition contains about 0.6 mg/mL of sodium ethyl parahydroxybenzoate. In further embodiments, the composition contains about 1.4 mg/mL of sodium methyl parahydroxybenzoate. In still another embodiment, the composition contains about 0.7 mg/mL of sodium ethyl parahydroxybenzoate.
  • a pH adjustor may be included in the composition.
  • the pH of the composition is adjusted to about 6.
  • the pH adjustor is an acid or base.
  • the pH adjustor is hydrochloric acid.
  • the pH adjustor is concentrated hydrochloric acid.
  • the pH adjustor is sodium hydroxide.
  • a pharmaceutical composition contains (i) about 70 mg/mL of Ibrutinib; (ii) about 13 mg/mL of microcrystalline cellulose and carboxymethylcellulose sodium; (iii) about 2.5 mg/mL of hydroxypropylmethylcellulose; (iv) about 1.5 mg/mL of citric acid monohydrate; (v) about 1.4 mg/mL of disodium hydrogen phosphate; (vi) about 1 mg/mL of sucralose; (vii) about 1 mg/mL of sodium methyl parahydroxybenzoate; and (viii) about 0.6 mg/mL of sodium ethyl parahydroxybenzoate.
  • a pharmaceutical composition contains (i) about 40 mg/mL of Ibrutinib; (ii) about 14 mg/mL of microcrystalline cellulose and carboxymethylcellulose sodium; (iii) about 1 mg/mL of hydroxypropylmethylcellulose; (iv) about 1.6 mg/mL of citric acid monohydrate; (v) about 1.4 mg/mL of disodium hydrogen phosphate; (vi) about 0.5 mg/mL of sucralose; (vii) about 1.4 mg/mL of sodium methyl parahydroxybenzoate; and (viii) about 0.7 mg/mL of sodium ethyl parahydroxybenzoate.
  • a pharmaceutical composition is provided and contains the components of Table 3.
  • step (i) is performed using hydrochloric acid or sodium hydroxide.
  • the process may also include adding water to the product of step (h) or (i). It is also envisioned that the product of step (a) may be homogenized using skill known in the art.
  • Liquid formulations may then be stored as a bulk unit or distributed into separate, smaller vials for storage or purchasing by the customer.
  • the liquid composition is added to a vial.
  • the vial is glass.
  • the vial is clear or amber.
  • the vial may be sealed.
  • the vial is sealed with a rubber stopper.
  • the vial is sealed with a Teflon coated rubber stopper. The stopper optionally contains a removable, i.e., tearable, aluminum cap.
  • the vial is a 10 mL/20 mm vial.
  • the vial is a drinking vial.
  • Preservatives may include ascorbic acid, BHT and BHA, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, or combinations thereof.
  • Sweeteners such as natural or artificial sweeteners, or a combination thereof, may be included in the compositions described herein.
  • the natural sweetener is sucrose including raw sugar, granulated sugar, brown sugar, confectioner's sugar, and turbinado sugar, fructose, honey, fruit sugar, high fructose corn syrup, corn syrup, sugar alcohols such as mannitol, sorbitol, xylitol, erythritol, hydrogenated starch hydrolysate, lactitol, or maltitol, osmalt, dextrose, invert sugar, agave nectar, glucose, lactose, maltose, maple sugar, date sugar, molasses, stevia extract, tagatose, trehalose, or any combinations thereof.
  • the artificial sweetener is sucralose, aspartame, saccharine, neotame, advantame, or acesulfame potassium.
  • Binders may include, without limitation, cellulose, methylcellulose, hydroxymethylcellulose, carboxymethylcellulose calcium, carboxymethylcellulose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, polypropylpyrrolidone, polyvinylpyrrolidone (povidone, PVP), gelatin, gum arabic and acacia, polyethylene glycols, starch, sugars such as sucrose, kaolin, dextrose, and lactose, cholesterol, tragacanth, stearic acid, gelatin, casein, lecithin (phosphatides), cetostearyl alcohol, cetyl alcohol, cetyl esters wax, dextrates, dextrin, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene stearates, polyvinyl alcohol, and gelatin, among
  • Lubricants may include anhydrous silicic acid, talc, stearic acid, sodium lauryl sulfate, magnesium stearate and sodium stearyl fumarate, among others.
  • Granulating agents may include, without limitation, silicon dioxide, starch, calcium carbonate, pectin, crospovidone, and polyplasdone.
  • the Ibrutinib compositions as described herein, whether in solid or liquid form, are stable under neutral conditions, i.e., a pH of about 6 to about 8.
  • the compositions are also stable under light irradiation.
  • the compositions are stable over a period of about 1 month for samples stored at varying temperatures and humidities.
  • the term stable as used herein refers to the compositions described herein which degrade less than about 3%.
  • the compositions are stable at about 20° C/50% relative humidity to about 45° C./75% relative humidity.
  • the compositions described herein degrade less than about 3% over a period of greater than 1 month at temperatures at or greater than about 25° C. and a relative humidity at or greater than about 60%.
  • Stability may be monitored by a number of methods known in the art.
  • the capsules and liquids may be observed to detect any physical aspect or color change.
  • a capsule color change or deformation of the capsule may indicate degradation or deterioration of capsule and thus affect safety or efficacy.
  • compositions described herein may be stored at reduced, room, or elected temperatures. In one embodiment, the compositions are stored at temperatures of about 0 to about 10° C. In another embodiment, the compositions are stored at temperatures of about 2 to about 8° C.
  • the compositions may be stored in the absence of water, air, and moisture. However, storage at room temperature, among other atmospheric conditions, does not affect the overall stability of the compositions.
  • compositions described herein are thereby useful in treating or preventing conditions.
  • the conditions are those recited in U.S. Pat. Nos. 8,497,277; 8,476,284; 8,703,780; and 8,754,090, which are incorporated by reference herein.
  • compositions are useful in therapeutically treating a subject having one or more of any of the conditions noted herein.
  • the compositions may also be prophylactically useful, i.e., the compositions may be administered to a patient susceptible to or otherwise at risk of developing a malignancy.
  • the compositions may further be used in maintenance therapy, i.e., administered to a patient who is in remission.
  • the methods include treating one or more autoimmune disease.
  • the autoimmune disorder is inflammatory bowel disease, arthritis, lupus, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, Sjogren's syndrome, multiple sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitisis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteriti
  • the methods include treating one or more heteroimmune disorder.
  • the heteroimmune disorder is graft versus host disease, transplantation, transfusion, anaphylaxis, allergy, type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, or atopic dermatitis.
  • the methods include treating one or more inflammatory disease.
  • the inflammatory disease is arthritis, asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis,
  • the methods include treating one or more cancer.
  • the cancer is a B-cell proliferative disorder.
  • the cancer is a hematological malignancy.
  • the cancer is B-cell prolymphocytic leukemia, leukemia, lymphoma, lymphoproliferative disorder, lymphoplasmacytic lymphoma, Waldenstrom macroglobulinemia, myeloid disorder, plasma cell myeloma, plasmacytoma, mediastinal large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, non-Hodgkin's CLL, SLL, high risk CLL, non-CLL/SLL lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, multiple myeloma, marginal zone lymphoma, non-Burkitt high grade B cell lympho
  • the B-cell proliferative disorder is non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, plasma cell myeloma, or chronic lymphocytic leukemia.
  • the B-cell proliferative disorder is diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma and Burkitt lymphoma.
  • the cancer is leukemia.
  • the cancer is a lymphoma.
  • the methods include treating a thromboembolic disorder.
  • the thromboembolic disorder is myocardial infarct, angina pectoris, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transitory ischemia, a peripheral arterial occlusive disorder, pulmonary embolism, or deep venous thrombosis.
  • the dosage requirements of Ibrutinib may vary based on the severity of the symptoms presented and the particular subject being treated. Treatment may be initiated with small dosages less than the optimum dose of Ibrutinib. Thereafter the dosage may be increased until the optimum effect under the circumstances is reached. Precise dosages will be determined by the administering physician based on experience with the individual subject treated. In one embodiment, the composition is administered at a concentration that will afford effective results without causing any unacceptable harmful or deleterious side effects.
  • the term “effective amount,” as used herein, refers to a sufficient amount of an agent or a compound being administered which will relieve one or more symptom of a B-cell proliferative disorder. The result may be reduction and/or alleviation of the signs, symptoms, or causes of the disorder. In certain embodiments, the effective amount achieves the desired pharmacologic effect or therapeutic improvement without undue adverse side effects.
  • compositions may be delivered to the subject by any suitable route as directed by the attending physician. In one embodiment, the compositions are delivered orally.
  • the second agent is one or more of actinomycines, alkylating agents, ahtretinoin, altretamine, amzacrine, anagrelide, angiogenesis inhibitors, antibody, anti-androgens, anti-estrogens, antimetabolites, anthracyclines, arsenic trioxide, asparaginase, B cell receptor pathway inhibitor (CD79A inhibitor, CD79B inhibitor, CD 19 inhibitor, Lyn inhibitor, Syk inhibitor, PI3K inhibitor, Blnk inhibitor, PLCy inhibitor, PKCP inhibitor), basiliximab, bexarotene, bortezomib, calcineurin inhibitors, canakinumab, celecoxib, ceradenovec, colchicine derivatives, cytotoxic antibiotics, daclizumab, denileukin diftitox, DNA damaging agent, epoxides, estramustine, estrogens, ethylene imines, folic acid analogues
  • kits or packages containing Ibrutinib and an optional carrier suitable for administration to a mammalian subject as discussed above.
  • the capsules may be packaged in bottles, blister packs, pill boxes, or the like.
  • the liquid formulation may be packaged in a bottle optionally coated with a piercable cap, ampule, drop counter, or in a saline bag.
  • the granules were then blended with a second portion of SLS (4.6 mg; Kolliphor; fine) and CCS (9.9 mg; Ac-di-sol). To this blend was then added a second portion of magnesium stearate (0.8 mg; Non-Bovine #5712) to provide a lubricated blend. This lubricated blend was then added to a size 0 Swedish orange hard gelatin capsule.
  • a liquid composition containing 70 mg/mL of Ibrutinib was prepared. Specifically, water (300 mL) was mixed with a composition MCC of CCS (Avicel RC591; 6.5 g) for 30 minutes. This dispersion was then homogenized for 30 seconds using a SILVERSON® homogenizer L2R at the maximal speed (7500 rpm). HPMC (2910 5 mPas; 1.25 g) was mixed with water (120 mL) until homogeneous using a magnetic stirrer. Micronized Ibrutinib (35 g, Lonza Clinical) was then added to the HPMC solution and mixed for 120 minutes. The MCC/CCS dispersion was then mixed with the Ibrutinib mixture.
  • Sucralose 0.5 g
  • sodium methyl parahydroxybenzoate (0.5725 g)
  • sodium ethyl parahydroxybenzoate (0.2875 g)
  • citric acid monohydrate (0.7565 g)
  • disodium hydrogen phosphate anhydrous parenteral (0.69 g) were then added to this mixture.
  • the mixture was stirred for about 10 minutes until the content solubilized.
  • the pH of the mixture was measured and found to be 5.99, thereby eliminating the need to adjust the pH.
  • the mixture was then diluted with purified water until a final weight of 510.5 g. The mixture was again measured and found to be about 6.
  • the concentration for each component in the final liquid composition is provided in Table 2.
  • a liquid composition containing 40 mg/mL of Ibrutinib was prepared. Specifically, water (300 mL) was mixed with a composition MCC of CCS (Avicel RC591; 7 g) for 30 minutes. This dispersion was then homogenized for 30 seconds using a SILVERSON® homogenizer L2R at the maximal speed (7500 rpm). HPMC (2910 5 mPas; 0.5 g) was mixed with water (120 mL) until homogeneous using a magnetic stirrer. Micronized Ibrutinib (20 g, Lonza Clinical) was then added to the HPMC solution and mixed for 120 minutes. The MCC/CCS dispersion was then mixed with the Ibrutinib mixture.
  • Sucralose (0.25 g), sodium methyl parahydroxybenzoate (0.6791 g) and sodium ethyl parahydroxybenzoate (0.3387 g) were added to the mixture.
  • citric acid monohydrate (0.801 g), and disodium hydrogen phosphate anhydrous parenteral (0.69 g) were then added to this mixture.
  • the mixture was stirred for about 10 minutes until the contents solubilized.
  • the pH of the mixture was measured and found to be about 5.99, thereby eliminating the need to adjust the pH.
  • the mixture was then diluted with purified water until final weight of 507 g. This mixture was then homogenized. The pH was again measured and found to be about 6.
  • the concentration for each component in the final liquid composition is provided in Table 3.
  • Purified water (480 g) was added to a vessel and warmed to about 83° C. at a stirring rate of about 400 rpm for about 60 minutes.
  • HPMC (10.002 g) was slowly added to the vessel and the mixture stirred at a rate of about 7600 rpm for about 4 minutes until the mixture was homogenized.
  • purified water (480 g) and then mixture was stirred for about 5 minutes at a rate of about 500 rpm at room temperature until the mixture was solubilized.
  • Ibrutinib (278.6 g) was added to the mixture and it was stirred at 600 rpm for about 2 h until it was homogenous. The mixture was monitored using a microscope for agglomerates.
  • the mixture in the first vessel was then added to the mixture in the second vessel and the combined contents stirred for about 5 minutes at a speed of about 500 rpm.
  • the first vessel was then rinsed using purified water (200 ml) and the same added to the second vessel. Under moderate stirring conditions, sucralose (4.0038 g), sodium methyl parahydroxybenzoate (4.5838 g), and sodium ethyl parahydroxybenzoate (2.300 g) were sequentially added to the second vessel and the mixture stirred for about 11 minutes until the solids solubilized.
  • Citric acid monohydrate (6.052 g) was then added to the second vessel and the mixture stirred for about 10 minutes.
  • Anhydrous disodium hydrogen phosphate (5.521 g) was then added and the mixture was stirred for about 10 minutes until the contents solubilized.
  • the pH of the solution was measured and found to be about 5.94, thereby eliminating the need to adjust the pH.
  • the mixture was then diluted using purified water (4064 g) until a final weight of 4084 g. This mixture was then homogenized. The pH was again measured and found to be about 5.98. Aliquots (8 ml) of the mixture were then removed under constant stirring at a speed of about 500 to about 1300 rpm over a period of about 75 minutes. Each aliquot was added to a an amber, glass vial (10 ml), a Flurotec coated rubber injection stopper (20 mm) then inserted into the vial, and the stopper affixed with an aluminum tear-off cap (20 mm). See, FIG. 3 .
  • the stability of the solid composition described herein was evaluated in 3 liquids. Specifically, the contents of 4 sprinkle capsules described herein (each containing 140 mg of solid composition) were dissolved in water (100 mL), milk (100 mL), and orange juice (100 mL) at room temperature. After about 6 hours, the colors of the milk and orange juice solutions remained unchanged, while the water solution turned milky white.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US15/092,195 2015-04-06 2016-04-06 Compositions Containing Ibrutinib Abandoned US20160287594A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US15/092,195 US20160287594A1 (en) 2015-04-06 2016-04-06 Compositions Containing Ibrutinib
US15/602,989 US20170252344A1 (en) 2015-04-06 2017-05-23 Compositions Containing Ibrutinib
US16/708,929 US20200171036A1 (en) 2015-04-06 2019-12-10 Compositions Containing Ibrutinib
US17/706,783 US20220211713A1 (en) 2015-04-06 2022-03-29 Compositions Containing Ibrutinib
US18/304,685 US20230263804A1 (en) 2015-04-06 2023-04-21 Compositions Containing Ibrutinib

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06
US15/092,195 US20160287594A1 (en) 2015-04-06 2016-04-06 Compositions Containing Ibrutinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/602,989 Division US20170252344A1 (en) 2015-04-06 2017-05-23 Compositions Containing Ibrutinib

Publications (1)

Publication Number Publication Date
US20160287594A1 true US20160287594A1 (en) 2016-10-06

Family

ID=55806788

Family Applications (5)

Application Number Title Priority Date Filing Date
US15/092,195 Abandoned US20160287594A1 (en) 2015-04-06 2016-04-06 Compositions Containing Ibrutinib
US15/602,989 Abandoned US20170252344A1 (en) 2015-04-06 2017-05-23 Compositions Containing Ibrutinib
US16/708,929 Abandoned US20200171036A1 (en) 2015-04-06 2019-12-10 Compositions Containing Ibrutinib
US17/706,783 Abandoned US20220211713A1 (en) 2015-04-06 2022-03-29 Compositions Containing Ibrutinib
US18/304,685 Pending US20230263804A1 (en) 2015-04-06 2023-04-21 Compositions Containing Ibrutinib

Family Applications After (4)

Application Number Title Priority Date Filing Date
US15/602,989 Abandoned US20170252344A1 (en) 2015-04-06 2017-05-23 Compositions Containing Ibrutinib
US16/708,929 Abandoned US20200171036A1 (en) 2015-04-06 2019-12-10 Compositions Containing Ibrutinib
US17/706,783 Abandoned US20220211713A1 (en) 2015-04-06 2022-03-29 Compositions Containing Ibrutinib
US18/304,685 Pending US20230263804A1 (en) 2015-04-06 2023-04-21 Compositions Containing Ibrutinib

Country Status (28)

Country Link
US (5) US20160287594A1 (ja)
EP (3) EP3280446A1 (ja)
JP (3) JP2018513852A (ja)
KR (2) KR20240013859A (ja)
CN (2) CN107530293A (ja)
AU (3) AU2016246669B2 (ja)
CA (1) CA2981601A1 (ja)
CL (1) CL2017002512A1 (ja)
DK (1) DK3892302T3 (ja)
EA (1) EA033992B1 (ja)
ES (1) ES2964472T3 (ja)
FI (1) FI3892302T3 (ja)
HK (1) HK1250925A1 (ja)
HR (1) HRP20231207T1 (ja)
HU (1) HUE063751T2 (ja)
IL (2) IL295941A (ja)
LT (1) LT3892302T (ja)
MA (2) MA41901A (ja)
MD (1) MD3892302T2 (ja)
MX (2) MX2017012822A (ja)
PH (1) PH12017501811A1 (ja)
PL (1) PL3892302T3 (ja)
PT (1) PT3892302T (ja)
RS (1) RS64653B1 (ja)
SG (2) SG11201707989PA (ja)
SI (1) SI3892302T1 (ja)
UA (1) UA125681C2 (ja)
WO (1) WO2016164404A1 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655857B2 (en) 2015-03-03 2017-05-23 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US9713617B2 (en) 2012-06-04 2017-07-25 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
CN107014943A (zh) * 2017-06-07 2017-08-04 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
US20180028537A1 (en) 2014-08-07 2018-02-01 Pharmacyclics Llc Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
WO2020039263A3 (en) * 2018-08-18 2020-04-09 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
WO2020039264A3 (en) * 2018-08-18 2020-04-30 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
CN112292117A (zh) * 2018-06-15 2021-01-29 詹森药业有限公司 包含依鲁替尼的配制品/组合物
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
US11478456B2 (en) 2017-08-19 2022-10-25 Azurity Pharmaceuticals, Inc. Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
US11730725B2 (en) 2017-09-26 2023-08-22 Tesaro, Inc. Niraparib formulations
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
CA3120960A1 (en) * 2018-11-30 2020-06-04 Janssen Biotech, Inc. Methods of treating follicular lymphoma
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
WO2022260667A1 (en) * 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Oral dosage forms of ibrutinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1877059T3 (pl) * 2005-04-28 2010-07-30 Wyeth Llc Mikroniozowany tanaproget i zawierające go kompozycje
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
US20140303191A1 (en) * 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2014004707A1 (en) * 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
EP2968808B1 (en) * 2013-03-14 2019-06-05 Fisher & Paykel Healthcare Limited Catheter mount with suction port
JPWO2015022942A1 (ja) * 2013-08-12 2017-03-02 横浜ゴム株式会社 プライマー組成物
CA2920534A1 (en) * 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
MX2017001671A (es) * 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ettmayer, P., et al. "Lessons Learned from Marketed and Investigational Prodrugs." J. Med. Chem. (2004) 47(10), pages 2393-2404. *
Han, H. "Targeted Prodrug Design to Optimize Drug Delivery." AAPS Pharmsci. (2000), Vol. 2 (1) article 6, pp. 1-11. *
Lymphoma Research Foundation. “Diffuse Large B-Cell Lymphoma (DLBCL).” © 2016. Available from: < http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6300153 >. *
Testa, B. "Prodrug research: futile or fertile?" Biochem. Pharm. (2004) 68, pages 2097-2106. *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266540B2 (en) 2012-06-04 2019-04-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10125140B1 (en) 2012-06-04 2018-11-13 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10106548B2 (en) 2012-06-04 2018-10-23 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9725455B1 (en) 2012-06-04 2017-08-08 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US9828383B1 (en) 2012-06-04 2017-11-28 Pharmacyclic s LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
US9713617B2 (en) 2012-06-04 2017-07-25 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10752634B2 (en) 2012-06-04 2020-08-25 Pharmacyclics Llc Crystalline forms of a brutons tyrosine kinase inhibitor
US10065968B2 (en) 2012-06-04 2018-09-04 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
US10294232B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10294231B2 (en) 2012-06-04 2019-05-21 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US10961251B1 (en) 2012-06-04 2021-03-30 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US20180028537A1 (en) 2014-08-07 2018-02-01 Pharmacyclics Llc Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
US10213386B2 (en) 2015-03-03 2019-02-26 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10828259B2 (en) 2015-03-03 2020-11-10 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US9655857B2 (en) 2015-03-03 2017-05-23 Pharmacyclics Llc Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US10010507B1 (en) 2015-03-03 2018-07-03 Pharmacyclics Llc Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943A (zh) * 2017-06-07 2017-08-04 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
US11529333B2 (en) 2017-08-19 2022-12-20 Azurity Pharmaceuticals, Inc. Oral pharmaceutical composition comprising zonisamide and process of preparation thereof
US11478456B2 (en) 2017-08-19 2022-10-25 Azurity Pharmaceuticals, Inc. Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof
US11730725B2 (en) 2017-09-26 2023-08-22 Tesaro, Inc. Niraparib formulations
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
CN112292117A (zh) * 2018-06-15 2021-01-29 詹森药业有限公司 包含依鲁替尼的配制品/组合物
GB2591396B (en) * 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
WO2020039264A3 (en) * 2018-08-18 2020-04-30 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
GB2591396A (en) * 2018-08-18 2021-07-28 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
WO2020039263A3 (en) * 2018-08-18 2020-04-09 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
US11931455B2 (en) 2018-08-18 2024-03-19 Liqmeds Worldwide Limited Pharmaceutical suspension for oral dosage
US12083222B2 (en) 2018-08-18 2024-09-10 Oncosol Limited Chemotherapeutic pharmaceutical suspension for oral dosage
US12097285B2 (en) 2018-08-18 2024-09-24 Liqmeds Worldwide Limited Mycophenolate oral suspension
US12097284B2 (en) 2018-08-18 2024-09-24 Liqmeds Worldwide Limited Mycophenolate oral suspension
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib

Also Published As

Publication number Publication date
US20200171036A1 (en) 2020-06-04
AU2016246669A1 (en) 2017-10-12
RS64653B1 (sr) 2023-10-31
MA54411A (fr) 2021-10-13
CN113546054A (zh) 2021-10-26
BR112017021325A2 (pt) 2018-06-26
US20170252344A1 (en) 2017-09-07
AU2021250925B2 (en) 2023-11-16
IL254695A0 (en) 2017-11-30
JP2018513852A (ja) 2018-05-31
DK3892302T3 (da) 2023-11-13
SG10202103458QA (en) 2021-05-28
HK1250925A1 (zh) 2019-01-18
IL254695B2 (en) 2023-02-01
EA201792224A1 (ru) 2018-06-29
LT3892302T (lt) 2023-11-10
MX2017012822A (es) 2018-06-13
KR20170134582A (ko) 2017-12-06
EP3892302B1 (en) 2023-09-06
CN107530293A (zh) 2018-01-02
MD3892302T2 (ro) 2024-03-31
AU2016246669B2 (en) 2021-07-15
US20230263804A1 (en) 2023-08-24
IL295941A (en) 2022-10-01
MA41901A (fr) 2021-04-14
MX2021015250A (es) 2022-01-24
KR20240013859A (ko) 2024-01-30
JP7438178B2 (ja) 2024-02-26
HRP20231207T1 (hr) 2024-01-19
PH12017501811A1 (en) 2018-04-23
PL3892302T3 (pl) 2024-03-11
EP4272835A2 (en) 2023-11-08
CA2981601A1 (en) 2016-10-13
SG11201707989PA (en) 2017-10-30
US20220211713A1 (en) 2022-07-07
AU2021250925A1 (en) 2021-11-11
AU2024200883A1 (en) 2024-02-29
ES2964472T3 (es) 2024-04-08
EP3892302B8 (en) 2023-10-18
HUE063751T2 (hu) 2024-01-28
EP3280446A1 (en) 2018-02-14
CL2017002512A1 (es) 2018-03-16
EP4272835A3 (en) 2023-12-20
KR102632745B1 (ko) 2024-02-01
MA54411B1 (fr) 2023-11-30
JP2024026087A (ja) 2024-02-28
EP3892302A1 (en) 2021-10-13
UA125681C2 (uk) 2022-05-18
PT3892302T (pt) 2023-11-15
WO2016164404A1 (en) 2016-10-13
IL254695B (en) 2022-10-01
EA033992B1 (ru) 2019-12-17
JP2022031690A (ja) 2022-02-22
SI3892302T1 (sl) 2023-11-30
FI3892302T3 (fi) 2023-11-03

Similar Documents

Publication Publication Date Title
US20220211713A1 (en) Compositions Containing Ibrutinib
US11642351B2 (en) Eslicarbazepine suspension
WO2018142336A1 (en) Lamotrigine suspension dosage form
JP2023500472A (ja) 経口乾燥溶液及び懸濁物のための医薬品単位用量システム
TWI727983B (zh) 物理及化學穩定之口服吉維諾司他（ｇｉｖｉｎｏｓｔａｔ）懸浮液、其用途及其製備方法
BR112017021325B1 (pt) Composições contendo ibrutinib, seu processo de preparação e uso
CN112292117A (zh) 包含依鲁替尼的配制品/组合物
US20190336443A1 (en) Ready-To-Use Liquid Parenteral Formulations Of Ribavirin
US11904046B1 (en) Hydrocortisone oral liquid formulations
WO2022115681A2 (en) Methods and compositions for oral pilocarpine liquid
US20230149359A1 (en) Stable pharmaceutical compositions of clonidine
Katona Formulation of microcomposites and pastilles using spray-drying and melt technology
CN115227658A (zh) 一种氨己烯酸固体制剂组合物
JP2010013357A (ja) 高含量ｌ−カルボシステインドライシロップ剤
CN106177973A (zh) 一种盐酸西替利嗪固体制剂及其制备方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: JANSSEN PHARMACEUTICA NV, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GUPTA, MANISH;TAMBWEKAR, KAUSTUBH;NAIR, BINURAJ KRISHNAN;AND OTHERS;SIGNING DATES FROM 20160611 TO 20161214;REEL/FRAME:040734/0372

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE